Search Results - "Wood, Matthew J."

Refine Results
  1. 1

    Advances in oligonucleotide drug delivery by Roberts, Thomas C., Langer, Robert, Wood, Matthew J. A.

    Published in Nature reviews. Drug discovery (01-10-2020)
    “…Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing…”
    Get full text
    Journal Article
  2. 2

    DNA Cage Delivery to Mammalian Cells by Walsh, Anthony S, Yin, HaiFang, Erben, Christoph M, Wood, Matthew J. A, Turberfield, Andrew J

    Published in ACS nano (26-07-2011)
    “…DNA cages are nanometer-scale polyhedral structures formed by self-assembly from synthetic DNA oligonucleotides. Potential applications include in vivo imaging…”
    Get full text
    Journal Article
  3. 3

    Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes by Wood, Matthew J A, Alvarez-Erviti, Lydia, Seow, Yiqi, Yin, HaiFang, Betts, Corinne, Lakhal, Samira

    Published in Nature biotechnology (01-04-2011)
    “…To realize the therapeutic potential of RNA drugs, efficient, tissue-specific and nonimmunogenic delivery technologies must be developed. Here we show that…”
    Get full text
    Journal Article
  4. 4

    An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies by McClorey, Graham, Wood, Matthew J

    Published in Current opinion in pharmacology (01-10-2015)
    “…Highlights • Recent human clinical trial data on RNAi approaches to gene down-regulation for genetic diseases. • Overview of current anti-microRNA drugs with…”
    Get full text
    Journal Article
  5. 5

    Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking by Murphy, Daniel E., de Jong, Olivier G., Brouwer, Maarten, Wood, Matthew J., Lavieu, Grégory, Schiffelers, Raymond M., Vader, Pieter

    Published in Experimental & molecular medicine (01-03-2019)
    “…Extracellular vesicles (EVs) are increasingly being recognized as mediators of intercellular signaling via the delivery of effector molecules. Interestingly,…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Therapeutic approaches for Duchenne muscular dystrophy by Roberts, Thomas C., Wood, Matthew J. A., Davies, Kay E.

    Published in Nature reviews. Drug discovery (01-11-2023)
    “…Duchenne muscular dystrophy (DMD) is a monogenic muscle-wasting disorder and a priority candidate for molecular and cellular therapeutics. Although rare, it is…”
    Get full text
    Journal Article
  8. 8

    The role of long non-coding RNAs in neurodevelopment, brain function and neurological disease by Roberts, Thomas C., Morris, Kevin V., Wood, Matthew J. A.

    “…Long non-coding RNAs (lncRNAs) are transcripts with low protein-coding potential that represent a large proportion of the transcriptional output of the cell…”
    Get full text
    Journal Article
  9. 9
  10. 10

    The Genesis of Pain in Osteoarthritis: Inflammation as a Mediator of Osteoarthritis Pain by Wood, Matthew J., Miller, Rachel E., Malfait, Anne-Marie

    Published in Clinics in geriatric medicine (01-05-2022)
    “…Chronic pain is a substantial personal and societal burden worldwide. Osteoarthritis (OA) is one of the leading causes of chronic pain and is increasing in…”
    Get full text
    Journal Article
  11. 11

    Extracellular Vesicle Heterogeneity: Subpopulations, Isolation Techniques, and Diverse Functions in Cancer Progression by Willms, Eduard, Cabañas, Carlos, Mäger, Imre, Wood, Matthew J A, Vader, Pieter

    Published in Frontiers in immunology (30-04-2018)
    “…Cells release membrane enclosed nano-sized vesicles termed extracellular vesicles (EVs) that function as mediators of intercellular communication by…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Targeting RNA to treat neuromuscular disease by Muntoni, Francesco, Wood, Matthew J. A

    Published in Nature reviews. Drug discovery (01-08-2011)
    “…Key Points Neuromuscular disorders comprise a heterogeneous group of clinical conditions that primarily affect one or more components of the neuromuscular unit…”
    Get full text
    Journal Article
  14. 14

    Antisense oligonucleotides: the next frontier for treatment of neurological disorders by Rinaldi, Carlo, Wood, Matthew J. A.

    Published in Nature reviews. Neurology (01-01-2018)
    “…Key Points Antisense oligonucleotides (ASOs) are short, synthetic, single-stranded oligodeoxynucleotides that can alter RNA and reduce, restore, or modify…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons by Heman-Ackah, Sabrina M, Manzano, Raquel, Hoozemans, Jeroen J M, Scheper, Wiep, Flynn, Rowan, Haerty, Wilfried, Cowley, Sally A, Bassett, Andrew R, Wood, Matthew J A

    Published in Human molecular genetics (15-11-2017)
    “…The recent generation of induced pluripotent stem cells (iPSCs) from a patient with Parkinson's disease (PD) resulting from triplication of the α-synuclein…”
    Get full text
    Journal Article
  18. 18

    Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum by Roberts, Thomas C, Coenen-Stass, Anna M L, Wood, Matthew J A

    Published in PloS one (19-02-2014)
    “…Extracellular microRNAs (miRNAs) are under investigation as minimally-invasive biomarkers for a wide range of disease conditions. We have recently shown in a…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Genetic therapies for RNA mis-splicing diseases by Hammond, Suzan M, Wood, Matthew J.A

    Published in Trends in genetics (01-05-2011)
    “…RNA mis-splicing diseases account for up to 15% of all inherited diseases, ranging from neurological to myogenic and metabolic disorders. With greatly…”
    Get full text
    Journal Article